Obesity & GLP-1 ETFs
OZEM — Roundhill GLP-1 & Weight Loss ETF
Roundhill · Active (GLP-1 value chain) · since 2024
Concentrated exposure to GLP-1 drugmakers and the manufacturers supplying them.
- Expense ratio
- 0.59%
- AUM
- $100M
- Dividend yield
- 0.8%
- 1Y return
- +12.6%
- 3Y ann.
- —
- 5Y ann.
- —
- 10Y ann.
- —
- All-time ann.
- —
Top holdings
- Eli Lilly19.40%
- Novo Nordisk14.10%
- Viking Therapeutics6.40%
- Amgen5.10%
- Zealand Pharma4.60%
25 total holdings · 62.0% in the top 10